




RealRate

# PHARMACEUTICAL 2018

## Statera Biopharma Inc. Rank 214 of 342





RealRate

# PHARMACEUTICAL 2018

## Statera Biopharma Inc. Rank 214 of 342



The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Statera Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 4.9% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	9,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,213
Liabilities, Non-Current	7.5
Other Assets	31
Other Compr. Net Income	184
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,294
Other Revenues	0
Property and Equipment	19
Research and Development	5,048
Selling, General and Administrative Expense	2,501

Output Variable	Value in 1000 USD
Assets	9,629
Liabilities	2,221
Expenses	7,549
Revenues	0
Stockholders Equity	7,408
Net Income	-9,843
Comprehensive Net Income	-9,751
Economic Capital Ratio	50%